Display options
Cite
Haberland A, Santos RA, Schimke I, et al. Are Agonistic Autoantibodies against G-Protein Coupled Receptors Involved in the Development of Long-Term Side Effects of Tumor Chemotherapy?. Case Rep Oncol. 2013;6(1):104-8doi: 10.1159/000348425.
Haberland, A., Santos, R. A., Schimke, I., & Wallukat, G. (2013). Are Agonistic Autoantibodies against G-Protein Coupled Receptors Involved in the Development of Long-Term Side Effects of Tumor Chemotherapy?. Case reports in oncology, 6(1), 104-8. https://doi.org/10.1159/000348425
Haberland, Annekathrin, et al. "Are Agonistic Autoantibodies against G-Protein Coupled Receptors Involved in the Development of Long-Term Side Effects of Tumor Chemotherapy?." Case reports in oncology vol. 6,1 (2013): 104-8. doi: https://doi.org/10.1159/000348425
Haberland A, Santos RA, Schimke I, Wallukat G. Are Agonistic Autoantibodies against G-Protein Coupled Receptors Involved in the Development of Long-Term Side Effects of Tumor Chemotherapy?. Case Rep Oncol. 2013 Jan;6(1):104-8. doi: 10.1159/000348425. Epub 2013 Feb 21. PMID: 23569443; PMCID: PMC3618042.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2013 Jan;6(1):104-8. doi: 10.1159/000348425. Epub 2013 Feb 21.

Are Agonistic Autoantibodies against G-Protein Coupled Receptors Involved in the Development of Long-Term Side Effects of Tumor Chemotherapy?.

Case reports in oncology

Annekathrin Haberland, Robson A S Santos, Ingolf Schimke, Gerd Wallukat

Affiliations

  1. Charité - Universitätsmedizin Berlin, Berlin, Germany.

PMID: 23569443 PMCID: PMC3618042 DOI: 10.1159/000348425

Abstract

Metabolic syndrome and cardiomyopathies are long-term consequences of chemo- and radiotherapy and develop long after completing the initial tumor treatment. The slow progression of such late effects might be an indication of the involvement of autoimmune processes in the development of such follow-up consequences. Functionally active autoantibodies, which permanently stimulate relevant cell receptors, might be a crucial component. Here, we report the detection of functionally active agonistic autoantibodies such as the autoantibody against the adrenergic alpha1-receptor, the muscarinic M2-receptor, and the newly discovered autoantibody against the Mas-receptor in the plasma of a cancer survivor following chemotherapy treatment.

Keywords: Agonistic autoantibodies; Cardiomyopathy; Chemotherapy; G-protein coupled receptor autoantibodies; Long-term disturbances; Metabolic syndrome; Tumor therapy

References

  1. Gut. 2001 Nov;49(5):699-705 - PubMed
  2. Eur J Heart Fail. 2012 Dec;14(12):1374-88 - PubMed
  3. Hypertension. 1997 Feb;29(2):678-82 - PubMed
  4. Scand J Immunol. 2004 Jul-Aug;60(1-2):189-98 - PubMed
  5. J Am Coll Cardiol. 2010 Nov 9;56(20):1644-50 - PubMed
  6. Circ Res. 2011 Oct 14;109(9):986-92 - PubMed
  7. J Exp Med. 1995 Jul 1;182(1):59-65 - PubMed
  8. Nat Rev Cardiol. 2010 Oct;7(10):564-75 - PubMed
  9. Exp Physiol. 2008 May;93(5):519-27 - PubMed
  10. Expert Rev Clin Immunol. 2011 Sep;7(5):659-74 - PubMed
  11. Methods Mol Biol. 2010;576:213-30 - PubMed
  12. Scand J Immunol. 2009 Aug;70(2):159-60 - PubMed
  13. Acta Histochem Suppl. 1988;35:145-9 - PubMed
  14. Hum Immunol. 2010 Jul;71(7):643-51 - PubMed
  15. J Clin Oncol. 2005 Jun 1;23(16):3718-25 - PubMed

Publication Types